BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase 3 Clinical Trial With Livatag® In Primary Liver Cancer
4/14/2014 4:04:07 PM
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB), in charge of the safety profile of the ReLive Phase III trial, today held its fourth meeting and once more unanimously recommended continuing the study without modification.
Help employers find you! Check out all the jobs and post your resume.
comments powered by